Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): Results of a European phase III study.

被引：0
|
作者：
Chan, S
Romieu, G
Huober, J
Delozier, T
Tubiana-Hulin, M
Lluch, A
Schneeweiss, A
Llombart, A
Carrasco, E
Fumoleau, P
机构：
[1] City Hosp Nottingham, Nottingham, England
[2] Ctr Val Aurelle, Montpellier, France
[3] Univ Tubingen, Tubingen, Germany
[4] Ctr Francois Baclesse, F-14021 Caen, France
[5] Ctr Rene Huguenin, St Cloud, France
[6] Hosp Clin Univ, Valencia, Spain
[7] Univ Heidelberg, Heidelberg, Germany
[8] Inst Valencia Oncol, Valencia, Spain
[9] Eli Lilly & Co, Alcobendas, Spain
[10] Ctr Georges Francois Leclerc, Dijon, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：24S / 24S
页数：1
相关论文
共 50 条
  • [31] Frontline docetaxel (T) capecitabine M combination therapy in patients (pts) with metastatic breast cancer (MBC): A phase II study.
    Chun, JH
    Lee, HG
    Lee, ES
    Kim, E
    Oh, JH
    Ro, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 71S - 71S
  • [32] Docetaxel plus capecitabine in the treatment of previous anthracycline-treated patients with metastatic breast cancer
    Bensalem, A.
    Bouzid, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [33] BUDGET IMPACT ANALYSIS OF EVEROLIMUS PLUS EXEMESTANE VERSUS GEMCITABINE PLUS PACLITAXEL AND CAPECITABINE PLUS DOCETAXEL IN METASTATIC BREAST CANCER PATIENTS IN EGYPT
    Elsisi, G.
    Saeed, E.
    Elmahdawy, M.
    VALUE IN HEALTH, 2014, 17 (07) : A622 - A622
  • [34] DOCETAXEL PLUS EPIRUBICIN VERSUS DOCETAXEL PLUS CAPECITABINE AS FIRST LINE TREATMENT IN PATIENTS WITH ADVANCED BREAST CANCER. FINAL RESULTS OF A MULTICENTER PHASE III TRIAL
    Mavroudis, D.
    Papakotoulas, P.
    Ardavanis, A.
    Kakolyris, S.
    Kouroussis, C.
    Malamos, N.
    Polyzos, A.
    Christophyllakis, C.
    Kentepozidis, N.
    Geirgoulias, V.
    ANNALS OF ONCOLOGY, 2008, 19 : 63 - 64
  • [35] A phase II trial of docetaxel in patients (PTS) with anthracycline resistant (AR) metastatic breast cancer (MBC)
    Guastalla, JP
    Bonneterre, J
    Fumoleau, P
    Piccart, M
    Tubiana, M
    Chevallier, B
    Nieamann, C
    Alakl, M
    Nichol, A
    Riva, A
    Marty, M
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 348 - 348
  • [36] A multicenter phase II trial of docetaxel plus gemcitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer
    N. Karachaliou
    Ch. Kouroussis
    P. Papakotoulas
    K. Kalbakis
    K. Tryfonidis
    N. Vardakis
    E. Poppis
    V. Georgoulias
    D. Mavroudis
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 1345 - 1352
  • [37] A multicenter phase II trial of docetaxel plus gemcitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer
    Karachaliou, N.
    Kouroussis, Ch
    Papakotoulas, P.
    Kalbakis, K.
    Tryfonidis, K.
    Vardakis, N.
    Poppis, E.
    Georgoulias, V.
    Mavroudis, D.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (05) : 1345 - 1352
  • [38] Capecitabine plus docetaxel plus bevacizumab as neoadjuvant therapy for invasive breast cancer: results of a phase II pilot study.
    Greil, R.
    Moik, M.
    Reitsamer, R.
    Ressler, S.
    Stoll, M.
    Namberger, K.
    Menzel, C.
    Mlineritsch, B.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S188 - S188
  • [39] COST-EFFECTIVENESS EVALUATION OF THE USE OF CAPECITABINE plus DOCETAXEL VS GEMCITABINE plus DOCETAXEL IN PATIENTS WITH RECURRENT BREAST CANCER WHO PREVIOUSLY FAILED TO ANTHRACYCLINE CHEMOTHERAPY AND/OR WITH METASTATIC DISEASE
    Tenorio, C.
    Vargas, J.
    Martinez, J.
    VALUE IN HEALTH, 2009, 12 (07) : A271 - A271
  • [40] Gemcitabine plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer
    Dong, Ningning
    Wu, Yongdong
    Song, Chenxin
    Wang, Mingyu
    Jiao, Yue
    Zhang, Shutian
    JOURNAL OF BUON, 2020, 25 (03): : 1348 - 1353
12345